U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications

Jan.21

On January 20, 2026, the U.S. Food and Drug Administration (FDA) posted meeting materials ahead of a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting scheduled for January 22, 2026, to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.

Key Takeaways

• On Jan. 20, 2026, FDA posted TPSAC meeting materials

• TPSAC will discuss MRTP applications for 20 ZYN nicotine pouch products submitted by Swedish Match USA, Inc.

• The virtual TPSAC meeting is scheduled for Jan. 22, 2026

• Public comment docket for the meeting: FDA-2025-N-0835-0020; closes at 11:59 p.m. ET on Jan. 21, 2026

• ZYN MRTP application docket: FDA-2025-N-0835-0001 (established June 18, 2025)

2Firsts, January 21, 2026

According to the U.S. Food and Drug Administration (FDA), on January 20, 2026, FDA posted meeting materials in preparation for a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.

FDA said the meeting materials include a draft agenda, backgrounders from Swedish Match USA, Inc. and FDA, and draft questions to the committee, available on the “2026 TPSAC Meeting Materials and Information” page. FDA also noted that the virtual TPSAC meeting is scheduled for January 22, 2026.

FDA said it established Docket No. FDA-2025-N-0835-0020 for public comment on this TPSAC meeting, with the comment period closing at 11:59 p.m. ET on January 21, 2026. FDA also noted that comments directed to the ZYN MRTP applications may be submitted to Docket No. FDA-2025-N-0835-0001, established on June 18, 2025.

Photo source: US Food and Drug Administration

References:

[1] January 22, 2026: Tobacco Products Scientific Advisory Committee Meeting on Swedish Match USA, Inc. MRTP Applications for ZYN Nicotine Pouch Products

Also Read:

[1] Federal Register notice: FDA seeks comments on “Warning Plans for Certain Tobacco Products”

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com